Chugai Pharmaceutical Co., Ltd

4519

JP3519400000

Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers, bones and joints diseases treatment, and kidney diseases. Net sales are distributed geographically as follows: Japan (57.3%), Switzerland (39.9%) and other (2,8%).

Employees

7,604

Sector

Pharmaceuticals

Calendar

2025-01-30 - Q4 2024 Earnings Release

More about the company

Income Statement and Estimates

income-statement-evolution-chart CHUGAI-PHARMACEUTICAL-CO-

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6,737.00JPY

Average target price

7,416.67JPY

Spread / Average Target

+10.09%

Consensus

Profit revisions

estimates-change-chart CHUGAI-PHARMACEUTICAL-CO-

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart CHUGAI-PHARMACEUTICAL-CO-

Company calendar

Market Closed - Japan Exchange Other stock markets 01:30:00 2024-12-11 am EST			5-day change	1st Jan Change
6,737.00 ^JPY	0.00%		-0.46%	+26.11%

Oct. 30	Jefferies Downgrades Chugai Pharmaceutical to Hold From Buy, Adjusts Price Target to 7,700 Yen From 7,100 Yen	MT
Oct. 25	Musk on top of Wall Street

Jefferies Downgrades Chugai Pharmaceutical to Hold From Buy, Adjusts Price Target to 7,700 Yen From 7,100 Yen	Oct. 30	MT
Musk on top of Wall Street	Oct. 25
Chugai Pharmaceutical's Nine-Month Profit Balloons 26%	Oct. 25	MT
Chugai Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the Financial Year Ending December 31, 2024	Oct. 25	CI
Jefferies Adjusts Chugai Pharmaceutical's Price Target to 7,100 Yen From 7,000 Yen, Keeps at Buy	Jul. 26	MT
Chugai Pharmaceutical Co., Ltd., Q2 2024 Earnings Call, Jul 25, 2024	Jul. 25
Maruishi Pharmaceutical Co.,Ltd. agreed to acquire MONILAC Business of Chugai Pharmaceutical Co., Ltd.	Jul. 21	CI
Financials lift Japanese shares on rate-hike speculation	Jul. 01	RE
Japan's Nikkei ends choppy session on stronger note	Jun. 24	RE
Japan's Nikkei squeezes out gains in choppy session	Jun. 23	RE
Japan's Nikkei rises on US stocks, heavyweight chip shares	Jun. 10	RE
Tech stocks lift Japan's Nikkei on boost from Nvidia's robust outlook	May. 22	RE
Japan's Nikkei drifts sideways as more earnings, US CPI awaited	May. 13	RE
Chugai Pharmaceutical Allots 594 Million Yen Worth of Shares as Restricted Stock Compensation	May. 01	MT
Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5%	Apr. 25	MT
Chugai Pharmaceutical's Profit Slightly Up in Q1	Apr. 24	MT
Japan's Nikkei slips on caution ahead of US inflation data	Apr. 09	RE
Chugai Pharmaceutical to Allocate 594 Million Yen of Treasury Shares as Restricted Stock Compensation	Mar. 29	MT
Roche's Chugai Wins Japanese Approval for Piasky Injection	Mar. 27	MT
Jefferies Adjusts Chugai’s Price Target to 7,000 Yen From 6,200 Yen, Keeps at Buy	Mar. 04	MT
Interest Rates, Central Bank Outlooks Churn Asian Stock Markets	Feb. 26	MT
Nikkei extends record rally on pharma boost	Feb. 25	RE
Nikkei hits record high as index heavyweights advance	Feb. 25	RE
US Tech Outlook Boost Asian Stock Markets	Feb. 22	MT
Global markets live: Sanofi, ABB, Qualcomm, Roche, Shell...	Feb. 01

Chugai Pharmaceutical Co., Ltd

Equities